La Roche-Posay, which is part of L'Oréal, has rolled out Effaclar Adapalene Gel 0.1% Acne Treatment, containing adapalene, a prescription-strength retinoid acne treatment. In addition, the skin care company is also also launching My Skin Track PoreScan, billed as its first skin analysis powered by artificial intelligence and developed with dermatologists.
 
La Roche-Posay’s topical prescription-strength retinoid (adapalene) acne treatment can be used in addition to its Effaclar Duo micronized benzoyl peroxide acne treatment. 

"There are many effective acne prescriptions including combinations of benzoyl peroxide and topical retinoids. However, many don't have access to these prescriptions because they don't visit a dermatologist or their insurance won't cover it. OTC prescription-strength acne treatments are a game-changer for people who have limited access to a health care provider. It allows earlier access to treatment which can help prevent scarring,” said Hilary Baldwin, MD, in a statement.

My Skin Track PoreScan uses AI to make personalized skincare recommendations for those concerned with clogged pores, raised imperfections and residual marks

"My Skin Track PoreScan not only provides consumers access to a personalized skincare regimen upon their initial skin analysis, but it also allows them to track changes in their skin after completing their regimen. This will provide insights into how to adapt their daily skincare routine with new product recommendations based on their new needs,” noted Adrien Dissous, VP of maketing for La Roche-Posay USA

My Skin Track PoreScan was presented at the Worldwide Congress of Dermatology in June.

La Roche-Posay My Skin Track PoreScan will be available at porescan.com in July 2019 and through the YouCam makeup app.